Press release
MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regulation
LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company,
About this update from Meiragtx Holdings Plc
[{"type":"text","content":"LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to provide an update on the Company’s AAV-hAQP1 Phase 1 AQUAx clinical trial for the treatment of radiation-induced xerostomia (RIX) on Tuesday, December 7, 2021, at 8:00 a.m. ET. MeiraGTx will also host a virtual R&D Day via webcast and conference call that will be held on Wednesday, December 15, 2021, from 10:00 a.m. to 12:00 p.m. ET to focus on the Company’s gene regulation platforms. The Phase 1 AQUAx conference call will include a clinical program update for product candidate AAV-hAQP1, a potential treatment for RIX, from MeiraGTx’s senior management as well as lead investigator Michael Brennan, DDS, Chairman of the Department of Oral Medicine and Director of the Sjögren’s Syndrome and Salivary Disorders Center at Atrium Health Carolinas Medical Center. A question and answer session will follow the formal presentation. MeiraGTx’s R&D Day webcast will feature presentations from Alexandria Forbes, Ph.D., President and Chief Executive Officer, and other members of the Company’s R&D team. The event will provide a detailed overview of the Company’s riboswitch gene regulation platform and an audience question and answer session. MeiraGTx’s xerostomia clinical program update details are as follows: Tuesday, December 7, 2021, at 8:00 a.m. ET.To register and attend the event, please click hereFor those who are unable to listen live, a replay of the call will be available by clicking here MeiraGTx’s virtual R&D Day details are as follows: Wednesday, December 15, 2021, from 10:00 a.m. to 12:00 p.m. ETA registration link and a link to the R&D Day will be provided closer to the event A live webcast of both events, as well as a replay, will be available on the Investors page of the Company’s website at www.investors.meiragtx.com/. About the Phase 1 AQUAx Clinical TrialThe Phase 1 AQUAx clinical trial is an open-label, non-randomized, dose escalation trial designed to evaluate the safety of MeiraGTx’s investigational gene therapy AAV-hAQP1 when administered via Stensen's duct to one or both parotid glands in patients who have been diagnosed with grade 2 or 3 radiation-induced xerostomia and who have remained cancer free for at l...